Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U12 small nuclear 2, pseudogene (RNU12-2P) is cataloged as a pseudogene, meaning it resembles the functional RNU12 gene but does not produce an active snRNA product or have a clearly defined biological function[1][5][6]. Unlike functional snRNA genes (like RNU12), which participate in minor spliceosome-mediated splicing of pre-mRNA[3], RNU12-2P lacks protein or catalytic activity and is not implicated as a receptor, enzyme, transporter, or other druggable molecular class. Despite database associations with microcephalic osteodysplastic primordial dwarfism, there is no clear evidence this pseudogene plays a direct pathogenic or therapeutic role; this likely reflects confusion with active snRNA genes such as RNU12. RNU12-2P is not targeted by approved or experimental drugs, and it is not used for biomarker applications or as an efficacy/safety monitoring agent. Context and clarification: - The functional U12 snRNA (RNU12) is part of the minor (U12-dependent) spliceosome and plays a direct role in splicing a small subset of introns[3]. - RNU12-2P is a non-functional, pseudogenic copy and should not be confused with the functional snRNA gene or minor spliceosome components. - There is no evidence supporting RNU12-2P as a drug target, biomarker, or having a role in therapy or disease other than database annotation artifacts[1][6]. If your intent was to find information on the **RNU12 snRNA gene**, which is a bona fide functional target and associated with splicing-related disorders, please clarify, as the entries here reflect only the pseudogene, not the functional component of the spliceosome[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U12 small nuclear 2, pseudogene (RNU12-2P).